BNP PARIBAS ASSET MANAGEMENT Holding S.A. Boosts Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 404,008 shares of the biopharmaceutical company’s stock after buying an additional 18,788 shares during the period. Regeneron Pharmaceuticals accounts for about 1.0% of BNP PARIBAS ASSET MANAGEMENT Holding S.A.’s investment portfolio, making the stock its 11th biggest holding. BNP PARIBAS ASSET MANAGEMENT Holding S.A. owned approximately 0.37% of Regeneron Pharmaceuticals worth $388,854,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of the stock. Nordea Investment Management AB increased its position in shares of Regeneron Pharmaceuticals by 23.2% in the 1st quarter. Nordea Investment Management AB now owns 29,195 shares of the biopharmaceutical company’s stock valued at $28,218,000 after acquiring an additional 5,495 shares during the period. Sierra Summit Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at $1,011,000. Susquehanna Fundamental Investments LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 1st quarter valued at $1,232,000. Sei Investments Co. increased its position in shares of Regeneron Pharmaceuticals by 8.1% in the 1st quarter. Sei Investments Co. now owns 24,407 shares of the biopharmaceutical company’s stock valued at $23,487,000 after acquiring an additional 1,839 shares during the period. Finally, Dynamic Technology Lab Private Ltd acquired a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at $749,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock traded down $9.37 during midday trading on Wednesday, reaching $1,085.62. The company had a trading volume of 461,177 shares, compared to its average volume of 471,236. The company has a market capitalization of $119.62 billion, a P/E ratio of 32.07, a P/E/G ratio of 2.24 and a beta of 0.13. Regeneron Pharmaceuticals, Inc. has a 12-month low of $715.54 and a 12-month high of $1,106.16. The firm’s fifty day simple moving average is $1,021.29 and its 200-day simple moving average is $969.42. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.27 and a quick ratio of 4.51.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). The company had revenue of $3.15 billion during the quarter, compared to analysts’ expectations of $3.19 billion. Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. As a group, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.17 EPS for the current year.

Insider Activity at Regeneron Pharmaceuticals

In related news, CEO Leonard S. Schleifer sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $979.25, for a total value of $24,481,250.00. Following the transaction, the chief executive officer now directly owns 408,200 shares of the company’s stock, valued at approximately $399,729,850. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,137 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $1,047.11, for a total value of $1,190,564.07. Following the transaction, the executive vice president now directly owns 12,931 shares of the company’s stock, valued at approximately $13,540,179.41. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Leonard S. Schleifer sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $979.25, for a total transaction of $24,481,250.00. Following the completion of the transaction, the chief executive officer now directly owns 408,200 shares in the company, valued at $399,729,850. The disclosure for this sale can be found here. In the last three months, insiders have sold 65,074 shares of company stock valued at $64,546,123. 7.48% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several research firms recently issued reports on REGN. Evercore ISI began coverage on Regeneron Pharmaceuticals in a research report on Tuesday, May 14th. They issued an “outperform” rating and a $1,150.00 target price on the stock. Canaccord Genuity Group reaffirmed a “buy” rating and set a $1,152.00 price target on shares of Regeneron Pharmaceuticals in a research report on Thursday, June 27th. UBS Group increased their price target on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the stock a “buy” rating in a research report on Wednesday, April 17th. Morgan Stanley cut their price target on Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating on the stock in a research report on Thursday, July 11th. Finally, TD Cowen increased their price target on Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $1,038.77.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.